0.9899
price down icon0.01%   -0.000100
pre-market  Pre-mercato:  .97   -0.0199   -2.01%
loading
Precedente Chiudi:
$0.99
Aprire:
$0.99
Volume 24 ore:
151.61K
Relative Volume:
0.13
Capitalizzazione di mercato:
$1.57M
Reddito:
$4.70M
Utile/perdita netta:
$-4.99M
Rapporto P/E:
-0.1542
EPS:
-6.42
Flusso di cassa netto:
$-5.29M
1 W Prestazione:
-13.92%
1M Prestazione:
+18.58%
6M Prestazione:
-40.72%
1 anno Prestazione:
-59.60%
Intervallo 1D:
Value
$0.89
$1.01
Intervallo di 1 settimana:
Value
$0.89
$1.21
Portata 52W:
Value
$0.4519
$7.20

Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile

Name
Nome
Salarius Pharmaceuticals Inc
Name
Telefono
346-772-0346
Name
Indirizzo
2450 HOLCOMBE BLVD, HOUSTON
Name
Dipendente
2
Name
Cinguettio
@SalariusPharma
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
SLRX's Discussions on Twitter

Confronta SLRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SLRX
Salarius Pharmaceuticals Inc
0.9899 1.57M 4.70M -4.99M -5.29M -6.42
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-04-27 Iniziato Ladenburg Thalmann Buy

Salarius Pharmaceuticals Inc Borsa (SLRX) Ultime notizie

pulisher
Jun 18, 2025

Salarius Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SLRX - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

What's Going On With Salarius Pharmaceuticals Shares Today? - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards - Nasdaq

Jun 17, 2025
pulisher
Jun 16, 2025

Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks

Jun 16, 2025
pulisher
Jun 11, 2025

Salarius Pharmaceuticals adjusts merger terms amid market shifts By Investing.com - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Salarius Pharmaceuticals adjusts merger terms amid market shifts - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Salarius Pharmaceuticals Enters Second Amendment To Merger Agreement With DecoySEC Filing - MarketScreener

Jun 11, 2025
pulisher
Jun 08, 2025

Comparing Schrödinger (NASDAQ:SDGR) & Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News

Jun 06, 2025
pulisher
May 27, 2025

Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.

May 27, 2025
pulisher
May 15, 2025

Salarius: Q1 Earnings Snapshot - New Haven Register

May 15, 2025
pulisher
May 07, 2025

Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 2.1% – Here’s Why - Defense World

May 07, 2025
pulisher
Apr 30, 2025

Financial Analysis: Hepion Pharmaceuticals (NASDAQ:HEPA) versus Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World

Apr 30, 2025
pulisher
Apr 27, 2025

Closing Figures Unveiled: Salarius Pharmaceuticals Inc (SLRX) Drop -26.34, Closes at 0.60 - DWinneX

Apr 27, 2025
pulisher
Apr 26, 2025

Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches By Investing.com - Investing.com Canada

Apr 26, 2025
pulisher
Apr 25, 2025

Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches - Investing.com

Apr 25, 2025
pulisher
Apr 16, 2025

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Robert S. Langer To Scientific Advisory Board - citybiz

Apr 16, 2025
pulisher
Apr 16, 2025

Decoy Therapeutics to Welcome MIT's Robert Langer to Advisory Board Post-Merger with Salarius (SLRX) | SLRX Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board - The Manila Times

Apr 16, 2025
pulisher
Apr 16, 2025

Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan

Apr 16, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 09, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Apr 09, 2025
pulisher
Apr 02, 2025

SLRX stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada

Apr 02, 2025
pulisher
Apr 02, 2025

SLRX stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 01, 2025

Contrasting Salarius Pharmaceuticals (NASDAQ:SLRX) & ASLAN Pharmaceuticals (NASDAQ:ASLN) - Defense World

Apr 01, 2025
pulisher
Mar 29, 2025

Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue By Investing.com - Investing.com India

Mar 29, 2025
pulisher
Mar 28, 2025

Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue - Investing.com

Mar 28, 2025
pulisher
Mar 27, 2025

Decoy Therapeutics’ antiviral candidates show broad activity against multiple viruses - BioWorld MedTech

Mar 27, 2025
pulisher
Mar 26, 2025

SLRX stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

SLRX stock touches 52-week low at $0.83 amid market challenges - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Revolutionary AI Platform Discovers Multi-Target Antiviral in Just 5 Days - Stock Titan

Mar 26, 2025
pulisher
Mar 24, 2025

Salarius Pharmaceuticals Advances Merger with Decoy Therapeutics to Enhance Development of Innovative Cancer and Viral Therapeutics - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 24, 2025
pulisher
Mar 21, 2025

Salarius Pharmaceuticals Inc. (SLRX) reports earnings - Quartz

Mar 21, 2025
pulisher
Mar 21, 2025

Salarius Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Mar 21, 2025
pulisher
Mar 19, 2025

Apraxia Treatment Market Size in 7MM is expected to grow at - openPR.com

Mar 19, 2025
pulisher
Mar 13, 2025

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

SLRX stock touches 52-week low at $0.9 amid market challenges - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

SLRX stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

Salarius Pharmaceuticals announces registered share offering By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

Salarius Pharmaceuticals announces registered share offering - Investing.com

Mar 11, 2025

Salarius Pharmaceuticals Inc Azioni (SLRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Capitalizzazione:     |  Volume (24 ore):